GFAP-ir glial analysis demonstrated an increase in CTCF of 47.6% in the Colitis group (2,636,322 ± 136,587) when compared to the Sham group (1,381,989 ± 107,950; p < 0.001) and a reduction of 39.8% in the Butyrate group (1,588,239 ± 32,304) when compared to the Colitis group (p < 0.001) (Figure 10D). The gene discussed is GFAP; the disease is colitis.